Company Overview - Guangju Energy's closing price on May 12 was 17.01 yuan, reflecting a 2.10% increase, with a rolling PE ratio of 85.88 times and a total market capitalization of 8.981 billion yuan [1] - The company operates in the oil industry, which has an average PE ratio of 12.64 times and a median of 25.95 times, placing Guangju Energy at the 18th position in the industry ranking [1] - As of the first quarter of 2025, 10 institutions held shares in Guangju Energy, with a total holding of 37,625.62 million shares valued at 7.138 billion yuan [1] Business Activities - Guangju Energy's main business activities include wholesale and retail of refined oil, storage, land and property leasing, chemical trading, and equity investments in power enterprises [1] - The company holds special operating qualifications for refined oil, liquefied petroleum gas, and hazardous chemicals, as well as qualifications for operating gas stations along highways in Guangdong Province [1] Financial Performance - In the first quarter of 2025, Guangju Energy reported an operating revenue of 327 million yuan, a year-on-year decrease of 37.87%, while net profit was 14.4972 million yuan, showing a year-on-year increase of 110.99% [1] - The sales gross margin for the company was 10.80% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Xinli Financial, which has a high PE ratio compared to its industry peers [1][2] - As of May 9, Xinli Financial's stock closed at 8.97 yuan, down 3.13%, with a rolling PE ratio of 130.78 times and a total market capitalization of 4.599 billion yuan [1] - The average PE ratio for the diversified financial industry is 70.45 times, with a median of 28.21 times, placing Xinli Financial at the 19th position among its peers [1][2] Group 2 - As of March 31, 2025, Xinli Financial had 84,726 shareholders, an increase of 20,527 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The main business activities of Xinli Financial include financing leasing, small loans, software and information technology services, pawn services, financing guarantees, and supply chain services [1] - In the latest quarterly report for Q1 2025, Xinli Financial reported operating revenue of 89.8757 million yuan, a year-on-year increase of 7.13%, and a net profit of 17.4284 million yuan, reflecting a year-on-year growth of 29.83%, with a gross profit margin of 81.55% [1]

从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均48.98倍，行业中值36.16倍，福瑞股份排 名第102位。 最新一期业绩显示，2025年一季报，公司实现营业收入3.30亿元，同比2.35%；净利润2863.67万元，同 比-32.97%，销售毛利率76.76%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)102福瑞股份84.3173.834.6983.64亿行业平均 48.9847.404.56104.17亿行业中值36.1637.662.3446.18亿1天益医疗-1712.92-2934.031.8321.83亿2澳华内 镜-592.52297.184.7562.44亿3诺唯赞-411.67-486.902.2688.10亿4爱朋医疗-344.10261.424.1528.23亿5博晖 创新-324.60515.093.4647.63亿6硕世生物-125.58-1835.121.1336.73亿7奥精医疗-121.29-177.781.6022.51亿 8睿昂基因-99.04-81.321.4012.82亿9康泰医学-82.90-70.042.9654.56亿10中红医疗-68.19 ...

Group 1 - The core viewpoint of the articles indicates that Haide Co., Ltd. is experiencing a decline in stock price and financial performance, with a current closing price of 5.59 yuan, down 2.10% [1] - The rolling price-to-earnings (PE) ratio for Haide Co. is 56.36, which is lower than the industry average of 70.45 and the industry median of 28.21, ranking 16th in the multi-financial industry [1][2] - As of the first quarter of 2025, six institutions hold shares in Haide Co., with a total holding of 149,862.38 thousand shares valued at 8.677 billion yuan [1] Group 2 - Haide Co. primarily engages in technology recovery of individual loan non-performing services, institutional distressed asset management, and quality asset management, with asset management as its main product and service [1] - The latest financial results for the first quarter of 2025 show that Haide Co. achieved an operating income of 2.21 billion yuan, a year-on-year decrease of 36.02%, and a net profit of 970.445 million yuan, down 58.40% year-on-year, with a gross profit margin of 98.91% [1]

Group 1 - The closing price of Beibu Gulf Port on May 9 was 8.52 yuan, down 1.39%, with a rolling PE ratio of 19.35 times and a total market capitalization of 19.819 billion yuan [1] - The average PE ratio for the shipping and port industry is 13.16 times, with a median of 14.27 times, placing Beibu Gulf Port at the 26th position in the industry ranking [1] - As of March 31, 2025, the number of shareholders for Beibu Gulf Port was 37,861, a decrease of 3,810 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Beibu Gulf Port Co., Ltd. specializes in container and bulk cargo handling, storage, port value-added services, and supporting port services, with main products including loading and unloading, towing services, cargo surveying, and agency services [1] - In the latest quarterly report for Q1 2025, the company achieved an operating income of 1.643 billion yuan, a year-on-year increase of 6.73%, while net profit was 196 million yuan, a year-on-year decrease of 49.87%, with a gross profit margin of 29.74% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Spring Medical, indicating a decline in stock price and a relatively high PE ratio compared to industry averages [1][2] - As of May 8, Spring Medical's stock closed at 15.48 yuan, down 2.03%, with a rolling PE ratio of 46.44 times and a total market capitalization of 5.938 billion yuan [1] - The average PE ratio for the medical device industry is 49.20 times, with a median of 36.56 times, placing Spring Medical at the 87th position in the industry ranking [1][2] Group 2 - As of March 31, 2025, Spring Medical had 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - In the latest quarterly report for Q1 2025, Spring Medical achieved an operating revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.0711 million yuan, reflecting a year-on-year growth of 5.20%, with a gross profit margin of 66.69% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kangtong Medical, indicating a significant decline in revenue and profit in the latest quarterly report [1][2] - As of May 8, Kangtong Medical's stock closed at 19.1 yuan, with a rolling PE ratio of 360.82, marking a new low in 22 days, and a total market capitalization of 1.91 billion yuan [1] - The average PE ratio for the medical device industry is 49.20, with a median of 36.56, positioning Kangtong Medical at the 119th rank within the industry [1][2] Group 2 - The latest quarterly report for Q1 2025 shows Kangtong Medical achieved revenue of 24.29 million yuan, a year-on-year decrease of 68.09%, and a net profit of 1.58 million yuan, down 85.25%, with a gross margin of 36.15% [1] - The company specializes in the research, design, manufacturing, integration, and operation services of medical gas equipment and systems, as well as medical clean equipment and systems [1] - As of April 30, 2025, Kangtong Medical had 8,242 shareholders, an increase of 22 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

Company Overview - Aibo Medical closed at 81.07 yuan, up 1.58%, with a rolling PE ratio of 40.65 times and a total market value of 15.366 billion yuan [1] - The company ranks 83rd in the medical device industry, which has an average PE ratio of 49.02 times and a median of 36.25 times [1] Shareholder Information - As of March 31, 2025, Aibo Medical had 9,729 shareholders, a decrease of 94 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - Aibo Medical focuses on the independent research, production, sales, and related services of ophthalmic medical devices, with main products including artificial lenses, surgical products, orthokeratology lenses, myopia control products, contact lenses, and other vision care products [1] Financial Performance - In the first quarter of 2025, Aibo Medical reported revenue of 357 million yuan, a year-on-year increase of 15.07%, and a net profit of 92.5581 million yuan, a year-on-year decrease of 10.05%, with a gross profit margin of 64.60% [1]

5月7日，佰仁医疗今日收盘112.35元，上涨1.33%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到90.53倍，总市值154.36亿元。 北京佰仁医疗科技股份有限公司是国内技术领先的、专注于动物源性植介入医疗器械研发与生产的高新 技术企业,主要产品主要包括心脏瓣膜置换与修复、先天性心脏病植介入治疗、外科软组织修复等。 最新一期业绩显示，2025年一季报，公司实现营业收入1.00亿元，同比31.30%；净利润3250.43万元， 同比290.69%，销售毛利率85.72%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)104佰仁医疗90.53105.4911.99154.36亿行业平均 49.0247.364.56104.18亿行业中值36.2537.322.4146.91亿1天益医疗-1703.20-2917.401.8221.70亿2澳华内 镜-638.65320.325.1267.31亿3诺唯赞-417.24-493.492.2989.29亿4爱朋医疗-335.34254.764.0427.52亿5博晖 创新-330.17523.933.5248.44亿6硕世生物-127.7 ...

Core Insights - Xianheng International's stock closed at 14.67 yuan, up 1.17%, with a rolling PE ratio of 25.54, marking a new low in 33 days, and a total market capitalization of 6.02 billion yuan [1] - The average PE ratio in the instrument and meter industry is 81.17, with a median of 51.72, placing Xianheng International at the 28th position in the industry ranking [1] - As of March 31, 2025, the number of shareholders for Xianheng International increased to 14,219, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Company Overview - Xianheng International Technology Co., Ltd. specializes in the MRO (Maintenance, Repair, and Operations) of tools and instruments, engaging in the research, production, sales, and related technical services of these products [1] - The main products of the company include tools, instruments, and services [1] Financial Performance - In the latest quarterly report for Q1 2025, the company achieved a revenue of 640 million yuan, representing a year-on-year increase of 46.04%, and a net profit of 21.57 million yuan, up 144.43%, with a gross profit margin of 21.46% [1]